Source:http://linkedlifedata.com/resource/pubmed/id/10095978
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6 Suppl
|
pubmed:dateCreated |
1999-6-1
|
pubmed:abstractText |
The aims of this paper were to present data on the pharmacokinetics, clearance, bioavailability, and in vivo absorption of etonogestrel (ENG); to present the results of a longitudinal analysis of the plasma concentration-time curves of ENG; and to present the results of a cross-sectional analysis on the association of body weight with serum ENG concentrations. Implanon had an absorption rate of almost 60 micrograms/day after 3 months, which slowly decreased to 30 micrograms/day at the end of 2 years. The bioavailability over this period of time was constant and close to 100%. The clearance remained around 7.5 L/h. With a bioavailability and clearance that remained constant, it was concluded that accumulation of ENG does not occur. After Implanon insertion, serum concentrations increased within 8 h to concentrations associated with ovulation inhibition. Maximum mean serum concentrations (Cmax) amounted to 813 pg/mL and the time (tmax) to reach Cmax was 4 days. After reaching Cmax, ENG serum concentrations declined to about 196 pg/mL at the end of the first year, followed by a slow decline to 156 pg/mL at the end of the third year. After removal of Implanon, serum ENG concentrations declined to levels less than the detection limit of the assay (20 pg/mL) within 1 week. Lower body weight was associated with higher serum ENG concentrations.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/3-keto-desogestrel,
http://linkedlifedata.com/resource/pubmed/chemical/Contraceptive Agents, Female,
http://linkedlifedata.com/resource/pubmed/chemical/Desogestrel,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Implants,
http://linkedlifedata.com/resource/pubmed/chemical/Progesterone Congeners,
http://linkedlifedata.com/resource/pubmed/chemical/Vinyl Compounds
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0010-7824
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
58
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
85S-90S
|
pubmed:dateRevised |
2005-3-10
|
pubmed:meshHeading |
pubmed-meshheading:10095978-Absorption,
pubmed-meshheading:10095978-Area Under Curve,
pubmed-meshheading:10095978-Biological Availability,
pubmed-meshheading:10095978-Body Weight,
pubmed-meshheading:10095978-Contraceptive Agents, Female,
pubmed-meshheading:10095978-Cross-Sectional Studies,
pubmed-meshheading:10095978-Desogestrel,
pubmed-meshheading:10095978-Drug Implants,
pubmed-meshheading:10095978-Female,
pubmed-meshheading:10095978-Humans,
pubmed-meshheading:10095978-Infusions, Intravenous,
pubmed-meshheading:10095978-Longitudinal Studies,
pubmed-meshheading:10095978-Progesterone Congeners,
pubmed-meshheading:10095978-Radioimmunoassay,
pubmed-meshheading:10095978-Vinyl Compounds
|
pubmed:year |
1998
|
pubmed:articleTitle |
Pharmacokinetics of Implanon. An integrated analysis.
|
pubmed:affiliation |
University of Vienna, General Hospital, Department of Obstetrics and Gynecology, Austria.
|
pubmed:publicationType |
Journal Article,
Retracted Publication,
Meta-Analysis
|